{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:37:07Z","timestamp":1782257827524,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,9]]},"DOI":"10.7759\/cureus.75432","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T06:35:01Z","timestamp":1733812501000},"source":"Crossref","is-referenced-by-count":1,"title":["Primary Cerebral Lymphoma With Isolated Vitreoretinal and Cerebral Recurrences Without Meningeosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Josef","family":"Finsterer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Gama Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri AJ","year":"2023","unstructured":"Ferreri AJ, Calimeri T, Cwynarski K, et al.. Primary central nervous system lymphoma. Nat Rev Dis Primers. 2023, 9:29. 10.1038\/s41572-023-00439-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008235","article-title":"Primary vitreoretinal lymphoma: a diagnostic and management challenge","volume":"138","author":"Soussain C","year":"2021","unstructured":"Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood. 2021, 138:1519-34. 10.1182\/blood.2020008235","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.2545","article-title":"Optic nerve infiltration in primary central nervous system lymphoma","volume":"74","author":"Ahle G","year":"2017","unstructured":"Ahle G, Touitou V, Cassoux N, et al.. Optic nerve infiltration in primary central nervous system lymphoma. JAMA Neurol. 2017, 74:1368-73. 10.1001\/jamaneurol.2017.2545","journal-title":"JAMA Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2020.1787460","article-title":"Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center","volume":"29","author":"Giuffr\u00e8 C","year":"2021","unstructured":"Giuffr\u00e8 C, Cicinelli MV, Marchese A, et al.. Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center. Ocul Immunol Inflamm. 2021, 29:472-8. 10.1080\/09273948.2020.1787460","journal-title":"Ocul Immunol Inflamm"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-010-0303-9","article-title":"Ocular involvement in patients with primary CNS lymphoma","volume":"102","author":"Hong JT","year":"2011","unstructured":"Hong JT, Chae JB, Lee JY, Kim JG, Yoon YH. Ocular involvement in patients with primary CNS lymphoma. J Neurooncol. 2011, 102:139-45. 10.1007\/s11060-010-0303-9","journal-title":"J Neurooncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2016.1139733","article-title":"Intraocular T-cell lymphoma: clinical presentation, diagnosis, treatment, and outcome","volume":"25","author":"Chaput F","year":"2017","unstructured":"Chaput F, Amer R, Baglivo E, et al.. Intraocular T-cell lymphoma: clinical presentation, diagnosis, treatment, and outcome. Ocul Immunol Inflamm. 2017, 25:639-48. 10.3109\/09273948.2016.1139733","journal-title":"Ocul Immunol Inflamm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2016.1139731","article-title":"Clinical characteristics of primary vitreoretinal lymphoma in an Indian population","volume":"25","author":"Mahajan S","year":"2017","unstructured":"Mahajan S, Nijhawan R, Rajwanshi A, et al.. Clinical characteristics of primary vitreoretinal lymphoma in an Indian population. Ocul Immunol Inflamm. 2017, 25:633-8. 10.3109\/09273948.2016.1139731","journal-title":"Ocul Immunol Inflamm"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff LR","year":"2022","unstructured":"Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022, 140:971-9. 10.1182\/blood.2020008377","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155500","article-title":"Vitreoretinal large B- cell lymphoma (VR- LBCL): clinical and pathological features and treatment outcomes","volume":"261","author":"Fadlelseed H","year":"2024","unstructured":"Fadlelseed H, Rhatigan M, Treacy M, Murphy C, O'Neill J, Kilmartin D, Kennedy S. Vitreoretinal large B- cell lymphoma (VR- LBCL): clinical and pathological features and treatment outcomes. Pathol Res Pract. 2024, 261:155500. 10.1016\/j.prp.2024.155500","journal-title":"Pathol Res Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2020.02.001","article-title":"Eye involvement in primary central nervous system lymphoma","volume":"65","author":"Farrall AL","year":"2020","unstructured":"Farrall AL, Smith JR. Eye involvement in primary central nervous system lymphoma. Surv Ophthalmol. 2020, 65:548-61. 10.1016\/j.survophthal.2020.02.001","journal-title":"Surv Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000326958.52546.f5","article-title":"Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients","volume":"71","author":"Fischer L","year":"2008","unstructured":"Fischer L, Martus P, Weller M, et al.. Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients. Neurology. 2008, 71:1102-8. 10.1212\/01.wnl.0000326958.52546.f5","journal-title":"Neurology"},{"key":"ref12","article-title":"Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities","volume":"25","author":"Ardenne M","year":"1975","unstructured":"Ardenne M, Reitnauer PG. Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities. Arzneimittelforschung. 1975, 25:1369-79.","journal-title":"Arzneimittelforschung"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06434-9","article-title":"Factors related to central nervous system involvement of primary vitreoretinal lymphoma","volume":"262","author":"Kim JY","year":"2024","unstructured":"Kim JY, Kim JJ, Kim RY, Kim M, Park YG, Park YH. Factors related to central nervous system involvement of primary vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol. 2024, 262:2421-9. 10.1007\/s00417-024-06434-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284953","article-title":"Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma","volume":"109","author":"Yoshifuji K","year":"2024","unstructured":"Yoshifuji K, Sadato D, Toya T, et al.. Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma. Haematologica. 2024, 109:3641-9. 10.3324\/haematol.2023.284953","journal-title":"Haematologica"},{"key":"ref15","article-title":"Primary central nervous system lymphoma treatment (PDQ\u00ae)","author":"PDQ Adult Treatment Editorial Board","year":"2002","unstructured":"PDQ Adult Treatment Editorial Board. Primary central nervous system lymphoma treatment (PDQ\u00ae). PDQ Cancer Information Summaries. National Cancer Institute (US), Bethesda, MD; 2002."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2018.0419","article-title":"The diagnosis and treatment of primary CNS lymphoma","volume":"115","author":"von Baumgarten L","year":"2018","unstructured":"von Baumgarten L, Illerhaus G, Korfel A, Schlegel U, Deckert M, Dreyling M. The diagnosis and treatment of primary CNS lymphoma. Dtsch Arztebl Int. 2018, 115:419-26. 10.3238\/arztebl.2018.0419","journal-title":"Dtsch Arztebl Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 Iloc study by the Lymphoma Study Association (LYSA) and the French oculo-cerebral lymphoma (LoC) network","volume":"117","author":"Soussain C","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, et al.. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u2018proof-of-concept\u2019 Iloc study by the Lymphoma Study Association (LYSA) and the French oculo-cerebral lymphoma (LoC) network. Eur J Cancer. 2019, 117:121-30. 10.1016\/j.ejca.2019.05.024","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000001937","article-title":"Cytarabine-induced peripheral neuropathy in a young patient with acute myeloid leukemia: a case report","volume":"86","author":"Karki K","year":"2024","unstructured":"Karki K, Adhikari S, Shrestha S, Bhandari J, Baral B, Baral A. Cytarabine-induced peripheral neuropathy in a young patient with acute myeloid leukemia: a case report. Ann Med Surg (Lond). 2024, 86:3082-5. 10.1097\/MS9.0000000000001937","journal-title":"Ann Med Surg (Lond)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-006-0443-1","article-title":"Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia","volume":"12","author":"Saito T","year":"2006","unstructured":"Saito T, Asai O, Dobashi N, et al.. Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia. J Infect Chemother. 2006, 12:148-51. 10.1007\/s10156-006-0443-1","journal-title":"J Infect Chemother"},{"key":"ref20","article-title":"Chemotherapy-induced peripheral neuropathy","volume":"6","author":"del Pino M","year":"2010","unstructured":"del Pino M. Chemotherapy-induced peripheral neuropathy. NCI Cancer Bull. 2010, 6:657-66.","journal-title":"NCI Cancer Bull"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/322186-primary-cerebral-lymphoma-with-isolated-vitreoretinal-and-cerebral-recurrences-without-meningeosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T06:35:03Z","timestamp":1733812503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/322186-primary-cerebral-lymphoma-with-isolated-vitreoretinal-and-cerebral-recurrences-without-meningeosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.75432","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,9]]}}}